Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01350245 · OUTCOME

Disease-Free Survival (DFS)

Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor · Source last updated 2025-05-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of patients
Interval / dispersion
Not reported
Time frame
1 year post-transplant

What was measured

1-year post-transplant disease free survival (DFS), defined as success if a patient is alive and disease free at 1-year post-transplant.

Groups in this outcome

TJU 2 Step Regimen

All patients treated on this trial will have hematological malignancies that are in remission at the time of the transplant. Their diseases would be expected to relapse with standard therapy alone. Total Body Irradiation (TBI): Total body irradiation given in 8 fractions over 4 days (total dose of 12 Gy). Donor Lymphocyte Infusion (DLI): After TBI, the patients will receive a dose of 2 x 10e8 of their donor's T cells. After this infusion, the patients will have 2 rest days. Cyclophosphamide: Cyclophosphamide is administered 2 days after the DLI to help tolerize the donor T cells. It is given at a dose of 60 mg/kg/d for 2 days Mycophenolate Mofetil (MMF): Started the day before the transplant to prevent graft versus host disease (GVHD) Tacrolimus: Started the day before the transplant to prevent graft-versus-host disease (GVHD) Hematopoietic stem cell transplantation (HSCT): One day after the cyclophosphamide is finished, the patients will receive a CD34 selected-do

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
TJU 2 Step Regimen28

Reported measurements

Source class 1
Values in percentage of patients · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
TJU 2 Step Regimen78.6Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        78.6
denoms
  1. counts
    1. group Id
      OG000
      value
      28
    units
    Participants
description
1-year post-transplant disease free survival (DFS), defined as success if a patient is alive and disease free at 1-year post-transplant.
groups
  1. description
    All patients treated on this trial will have hematological malignancies that are in remission at the time of the transplant. Their diseases would be expected to relapse with standard therapy alone. Total Body Irradiation (TBI): Total body irradiation given in 8 fractions over 4 days (total dose of 12 Gy). Donor Lymphocyte Infusion (DLI): After TBI, the patients will receive a dose of 2 x 10e8 of their donor's T cells. After this infusion, the patients will have 2 rest days. Cyclophosphamide: Cyclophosphamide is administered 2 days after the DLI to help tolerize the donor T cells. It is given at a dose of 60 mg/kg/d for 2 days Mycophenolate Mofetil (MMF): Started the day before the transplant to prevent graft versus host disease (GVHD) Tacrolimus: Started the day before the transplant to prevent graft-versus-host disease (GVHD) Hematopoietic stem cell transplantation (HSCT): One day after the cyclophosphamide is finished, the patients will receive a CD34 selected-do
    id
    OG000
    title
    TJU 2 Step Regimen
param Type
NUMBER
reporting Status
POSTED
time Frame
1 year post-transplant
title
Disease-Free Survival (DFS)
type
PRIMARY
unit Of Measure
percentage of patients

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice